Schroder Investment Management Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Schroder Investment Management Group’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-71,643	Closed	-$1.53M	–	1144
2025 Q3	$1.53M	Buy	+71,643	New	+$1.69M	﹤0.01%	972
2025 Q2	–	Sell	-272,882	Closed	-$4.66M	–	1153
2025 Q1	$4.66M	Buy	272,882 +4,848	+2%	+$88.1K	﹤0.01%	768
2024 Q4	$4.47M	Sell	268,034 -264,938	-50%	-$4.28M	﹤0.01%	783
2024 Q3	$8.36M	Buy	532,972 +400,110	+301%	+$6.67M	0.01%	696
2024 Q2	$2.16M	Hold	132,862	–	–	﹤0.01%	919
2024 Q1	$2.46M	Buy	132,862 +71,160	+115%	+$1.76M	﹤0.01%	894
2023 Q4	$1.93M	Buy	+61,702	New	+$1.47M	﹤0.01%	915

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Schroder Investment Management Group's ACAD Position: Q4 2025 in Review

Schroder Investment Management Group sold out of Acadia Pharmaceuticals (ACAD) in Q4 2025, closing a stake of 71,643 shares — an estimated $1.53M sold.

Schroder Investment Management Group first reported a position in ACAD in Q4 2023 and held it in 7 quarters. The position peaked at $8.36M in Q3 2024. 336 funds tracked by Wall St. Rank hold ACAD as of Q4 2025.

Schroder Investment Management Group reported no remaining Acadia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Schroder Investment Management Group sold 71,643 Acadia Pharmaceuticals shares in Q4 2025, an estimated $1.53M.
Schroder Investment Management Group first reported a position in Acadia Pharmaceuticals in Q4 2023 and held it in 7 quarters.
Schroder Investment Management Group's Acadia Pharmaceuticals position peaked at $8.36M in Q3 2024.
336 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2025.

Based on Schroder Investment Management Group's 13F filing for Q4 2025, filed 13 Feb 2026.